BVF GP HOLDINGS LLC 3
3 · CTI BIOPHARMA CORP · Filed Mar 4, 2020
Insider Transaction Report
Form 3
BVF GP HOLDINGS LLC
10% Owner
Holdings
- 2,109,280(indirect: See footnote)
Common Stock, $0.001 par value
- (indirect: See footnote)
Series O Preferred Stock, $0.001 par value
→ Common Stock, par value $0.001 (3,754,000 underlying) - 3,041,120(indirect: See footnote)
Common Stock, $0.001 par value
- (indirect: See footnote)
Series O Preferred Stock, $0.001 par value
→ Common Stock, par value $0.001 (2,426,667 underlying)
Footnotes (4)
- [F1]This Form 3 is filed jointly by BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP") and BVF GP HOLDINGS LLC ("BVF GPH", and together with BVF GP and BVF2 GP, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.
- [F2]Securities owned directly by Biotechnology Value Fund, L.P. ("BVF"). As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF.
- [F3]Securities owned directly by Biotechnology Value Fund II, L.P. ("BVF2"). As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2.
- [F4]The Series O Convertible Preferred Stock, par value $0.001 per share (the "Series O Preferred Stock") have no expiration date, and are convertible upon issuance; the conversion ratio is 667 shares of Common Stock for 1 share of Series O Preferred Stock. The Series O Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934,as amended, more than 19.99% of the shares of Common Stock outstanding immediately after giving effect to such conversion.